日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Mass Spectrometry-Based Proteomics Analysis of Nasal Fluid Uncovers Differentially Expressed Proteins as Potential Biomarkers of Allergic Asthma

基于质谱的鼻腔液蛋白质组学分析揭示了差异表达蛋白作为过敏性哮喘的潜在生物标志物

Rosado Alicea, Jamie A; Morton, Shad; Brown, Alyson N; Budnik, Bogdan; Akenroye, Ayobami; Ahmad, Rushdy; Laidlaw, Tanya M

The ratio of circulatory levels of sphingolipids to steroids predicts asthma exacerbations

循环系统中鞘脂与类固醇的比值可预测哮喘急性发作

Chen, Yulu; Zhang, Pei; Huang, Mengna; Kachroo, Priyadarishini; Checa, Antonio; Chen, Qingwen; Mendez, Kevin; Stav, Meryl; Prince, Nicole; Begum, Sofina; Aparicio, Andrea; Guo, Tao; Sharma, Rinku; Chu, Su H; Kelly, Rachel S; Hecker, Julian; Akenroye, Ayobami; Dahlin, Amber; Weiss, Scott T; McGeachie, Michael; Wheelock, Craig E; Lasky-Su, Jessica A

Integrative epidemiology and immunotranscriptomics uncover a risk and potential mechanism for cutaneous lymphoma unmasking or progression with dupilumab therapy

整合流行病学和免疫转录组学揭示了度普利尤单抗治疗可能导致皮肤淋巴瘤显现或进展的风险和潜在机制

Cabrera-Perez, Javier S; Carey, Vincent J; Odejide, Oreofe O; Singh, Sonal; Kupper, Thomas S; Pillai, Shiv S; Weiss, Scott T; Akenroye, Ayobami

Targeting alarmins in asthma: From bench to clinic

靶向哮喘报警素:从实验室到临床

Akenroye, Ayobami; Boyce, Joshua A; Kita, Hirohito

Race and ethnicity, not just insurance, is associated with biologics initiation in asthma and related conditions

种族和民族,而不仅仅是保险,与哮喘及相关疾病的生物制剂治疗启动有关。

Akenroye, Ayobami; Hvisdas, Christopher; Stern, Jessica; Jackson, John W; Louisias, Margee

Impact of clinical factors and season on inflammatory cytokines in biologic-treated and untreated asthma

临床因素和季节对生物制剂治疗和未治疗哮喘患者炎症细胞因子的影响

Nopsopon, Tanawin; Cabrera-Perez, Javier; Lee, Pui Y; Brodeur, Kailey E; Lugogo, Njira L; Hsu, Evan E; LeSon, Courtney; Hahn, Georg; Carr, Steven A; Weiss, Scott T; Akenroye, Ayobami

Machine learning-derived genetic risk scores identify IL21 as a predictor of response to omalizumab and dupilumab in asthma

基于机器学习的遗传风险评分表明,IL21 可预测哮喘患者对奥马珠单抗和度普利尤单抗的反应。

Akenroye, Ayobami; Zhang, Chengyue; Nopsopon, Tanawin; Kalra, Sean; Weiss, Scott T; Moll, Matthew R

Advancing equity in allergy and immunology: progress, pitfalls, and the path forward

推进过敏和免疫学领域的公平性:进展、挑战与未来之路

Mendez, Philip; Akenroye, Ayobami; Nyenhuis, Sharmilee M; Cardet, Juan Carlos

Patients with Higher Exacerbation Burden and Eosinophil Counts are More Likely to Require Multiple Biologics for Asthma Control

哮喘急性发作频率较高和嗜酸性粒细胞计数较高的患者更可能需要多种生物制剂来控制哮喘。

Brown, Alyson N; Nopsopon, Tanawin; Akenroye, Ayobami

Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA Study

抗IgE生物制剂奥马珠单抗治疗成人重度哮喘临床疗效的生物标志物预测因子:SoMOSA研究结果

Djukanović, Ratko; Brinkman, Paul; Kolmert, Johan; Gomez, Cristina; Schofield, James; Brandsma, Joost; Shapanis, Andy; Skipp, Paul J S; Postle, Anthony; Wheelock, Craig; Dahlen, Sven-Erik; Sterk, Peter J; Brown, Thomas; Jackson, David J; Mansur, Adel; Pavord, Ian; Patel, Mitesh; Brightling, Christopher; Siddiqui, Salman; Bradding, Peter; Sabroe, Ian; Saralaya, Dinesh; Chishimba, Livingstone; Porter, Joanna; Robinson, Douglas; Fowler, Stephen; Howarth, Peter H; Little, Louisa; Oliver, Thomas; Hill, Kayleigh; Stanton, Louise; Allen, Alexander; Ellis, Deborah; Griffiths, Gareth; Harrison, Tim; Akenroye, Ayobami; Lasky-Su, Jessica; Heaney, Liam; Chaudhuri, Rekha; Kurukulaaratchy, Ramesh